An examination of plasma autoantibodies against voltage gated calcium channels in schizophrenia

McLean, Ryan Thomas; Buist, Elizabeth; Clair, David St; Wei, Jun

doi:10.1016/j.bbih.2023.100603

Cited by 1 publication

(1 citation statement)

References 35 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neural autoantibody-associated psychiatric disease is an increasing phenomenon in psychiatry affecting different psychiatric patient groups [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. It is a significant phenomenon associated with approximately 23% of affective disorders [ 16 ], 17% of schizophrenic disorders [ 16 ], and 27% of disorders with cognitive dysfunction [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Course of Neural Autoantibody-Associated Psychiatric Disorders: Retrospective Data from a Specifically Immunopsychiatric Outpatient Clinic

Hansen

Rentzsch²,

Hirschel

et al. 2023

Antibodies

View full text Add to dashboard Cite

Background: Autoantibody-associated psychiatric disorders are a new terrain that is currently underrepresented considering immunopsychiatry’s potential importance for therapeutic aspects. The aim of our research was thus to present initial pilot data on the long-term clinical course of our patients in an outpatient clinic specializing in autoantibody-associated psychiatric disorders. Methods: Thirty-seven patients were examined clinically in our outpatient clinic at regular intervals over a 1.5-year period. We collected clinical data on their demographics, psychopathology, and cognition, and magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) data as well as the status of neural autoantibodies in blood and/or serum. Results: Our main finding was that affective, psychotic, and cognitive symptoms did not change significantly over the 1.5-year period, thus revealing no progression. We divided the entire cohort of autoantibody-positive patients (n = 32) into subgroups consisting of patients with dementia (n = 14), mild cognitive impairment (MCI) (n = 7), psychotic disorders (n = 6), and a CSF profile of Alzheimer’s disease (n = 6). Relying on established classification schemes, we identified the following percentages in our autoantibody-positive cohort: 28% with autoimmune encephalitis, 15% with autoimmune psychosis, and 63% with autoimmune psychiatric syndromes. Discussion: These initial pilot results suggest that autoantibody-associated diseases do not show a significantly progressive course in the long-term and are often characterized by impaired verbal memory recall when cognitive impairment progresses to dementia. These initial data need to be verified in larger cohorts. We believe that this pilot study underscores the importance of promoting such a specialized outpatient clinic to better characterize various aspects of autoantibody-mediated psychiatric disorders.

show abstract